Invitrogen Shares Climb 5.4 Percent on Strong Q4, Flu Deal, Stock Upgrade | GenomeWeb

NEW YORK, March 1 (GenomeWeb News) - Shares in Invitrogen were up $3.85, or 5.43 percent, at $74.78 in afternoon trade after the company reported strong fourth-quarter earnings, disclosed a deal to help develop a process for incorporating an avian H5 influenza antigen, and was upgraded by an investment bank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.